DENTSPLY SIRONA VP receives new stock and option awards

DENTSPLY SIRONA Inc. executive Kevin Czerney, VP and Chief Accounting Officer, reported equity awards granted on March 4, 2026.

Rhea-AI Filing Summary

DENTSPLY SIRONA Inc. executive Kevin Czerney, VP and Chief Accounting Officer, reported equity awards granted on March 4, 2026. He received stock options for 10,400 shares and a grant of 13,690 shares of common stock.

The common stock award consists entirely of restricted stock units that vest in one-third installments over three years, ending March 4, 2029. The stock options also vest in one-third annual increments through March 4, 2029 and carry an exercise price equal to 110% of the closing share price on the grant date.

Insider Trade Summary

Grant/Award: 24,090 shares

Grant/Award 2 txns

Insider Czerney Kevin

Role VP, Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	10,400	$0.00	$0.00
Grant/Award	Common Stock	13,690	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 10,400 contracts (Direct); Common Stock — 41,268.908 shares (Direct)

Footnotes (2)

1. F1. Award consists entirely of Restricted Stock Units (RSUs) which vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029.
2. F2. Stock options vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029, with an exercise price equal to 110% of the closing price of the Issuer's common stock as of the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did DENTSPLY SIRONA (XRAY) report for Kevin Czerney?

Kevin Czerney received equity awards consisting of stock options and restricted stock units. The filing shows 10,400 stock options and 13,690 shares of common stock granted, all reported as acquisitions rather than open‑market purchases or sales, reflecting compensation rather than trading activity.

How many DENTSPLY SIRONA (XRAY) stock options were granted to Kevin Czerney?

Kevin Czerney was granted stock options covering 10,400 shares. According to the filing, these options vest in equal one‑third installments over three years, ending March 4, 2029, and have an exercise price set at 110% of the common stock’s closing price on the grant date.

What restricted stock unit (RSU) grant did Kevin Czerney receive from DENTSPLY SIRONA (XRAY)?

Kevin Czerney received an award of 13,690 shares of common stock in the form of restricted stock units. The RSUs vest in one‑third annual installments over a three‑year period ending March 4, 2029, aligning his compensation with multi‑year company performance and retention goals.

How do Kevin Czerney’s new DENTSPLY SIRONA (XRAY) equity awards vest over time?

Both the RSUs and stock options vest in equal one‑third installments over three years. Vesting runs through March 4, 2029, meaning portions of the 13,690 RSUs and 10,400 options become exercisable or deliver shares annually, supporting long‑term executive incentive alignment.

What is the exercise price structure of Kevin Czerney’s DENTSPLY SIRONA (XRAY) stock options?

The stock options granted to Kevin Czerney have an exercise price equal to 110% of the common stock’s closing price on the grant date. This premium pricing typically requires future stock price appreciation before the options provide intrinsic economic value to the holder.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 05:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Czerney Kevin

(Last) (First) (Middle)

C/O DENTSPLY SIRONA INC

13320-B BALLANTYNE CORPORATE PLACE

(Street)

CHARLOTTE NC 28277

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DENTSPLY SIRONA Inc. [ XRAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		13,690(1)	A	$0	41,268.908	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.78	03/04/2026		A		10,400		03/04/2027(2)	03/04/2036	Common Stock	10,400	$0	10,400	D

Explanation of Responses:

1. Award consists entirely of Restricted Stock Units (RSUs) which vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029.

2. Stock options vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029, with an exercise price equal to 110% of the closing price of the Issuer's common stock as of the date of grant.

	/s/ Jessica Nielsen Causey, Attorney-In-Fact for Kevin Czerney	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.